Johnson & Johnson (JNJ) shares rose 0.4% in early trading Friday after the company received U.S. Food and Drug Administration (FDA) approval for its RYBREVANT FASPRO (amivantamab combined with hyaluronidase) to be used alongside lazertinib as a first-line treatment for EGFR-mutated non-small cell lung cancer. The therapy enables subcutaneous administration in just five minutes.